FibroGen Reports First Quarter 2024 Financial Results
06 mai 2024 16h02 HE
|
FibroGen, Inc.
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in...
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
20 févr. 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close....
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
05 févr. 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
25 janv. 2024 07h00 HE
|
FibroGen, Inc.
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024Pamrevlumab is the first experimental arm...
FibroGen Reports First Quarter 2023 Financial Results
08 mai 2023 16h01 HE
|
FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
17 sept. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network ...